Description

Retaspimycin Hydrochloride is a potent ansamycin antibiotic and a semi-synthetic derivative of geldanamycin, functioning as a highly specific inhibitor of Heat Shock Protein 90 (Hsp90). This compound is critical for disrupting the Hsp90 chaperone function, which is essential for the stability and activity of numerous oncogenic client proteins in cancer cells. It is primarily utilized by pharmaceutical researchers and developers in oncology drug discovery, serving as a key reference standard and a promising candidate for the development of novel anti-cancer therapeutics.

Application

• Oncology Research & Drug Discovery: As a potent Hsp90 inhibitor for studying tumor cell proliferation, apoptosis, and signal transduction pathways.
• Reference Standard: For analytical method development, validation, and quality control in pharmaceutical R&D and manufacturing.
• Preclinical Development: Evaluation of pharmacokinetics, pharmacodynamics, and efficacy in animal models of various cancers.
• Biochemical Assays: Used in high-throughput screening (HTS) and in vitro studies to identify and characterize Hsp90-dependent processes.
• Combination Therapy Studies: Investigation of synergistic effects with other chemotherapeutic agents or targeted therapies.
• Mechanism of Action Studies: Fundamental research into the role of Hsp90 in protein folding, cellular stress response, and disease mechanisms.

Basic Information

Product Name	Retaspimycin Hydrochloride
CAS No.	857402-63-2
Molecular Formula	C31H44ClN3O8
Molecular Weight	622.15 g/mol
Synonyms	IPI-504; Hydrochloride salt of Retaspimycin; 17-Demethoxy-17-allylamino-18,21-didehydrogeldanamycin hydrochloride; 17-AAG Hydrochloride (related analogue); Ansamycin Hydrochloride derivative; Hsp90 Inhibitor IPI-504; (15Z)-15-[(2S,3E,5S)-3-(Allylamino)-5-hydroxy-2-methyl-2,8-dioxo-1-oxa-6-azaspiro[4.5]dec-3-en-7-yl]-7,9-dihydroxy-8,19,21-trimethoxy-4,10,23-trimethyl-3,20-dioxo-3,4,11,22-tetrahydro-23H-26-epoxy-7,10-methanobenzo[d]cyclonona[1,2-f][1,7,10]trioxadiazacyclooctadecine-6-carboxamide hydrochloride
EINECS	Contact for details

Quality Control

Our Retaspimycin Hydrochloride is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing to ensure identity, purity, and consistency. We provide comprehensive Certificates of Analysis (COA) detailing specifications such as assay (HPLC), related substances, residual solvents, and water content. Our quality commitment supports its use as a critical material in pharmaceutical research and development.

Storage

Preserve in a tightly closed container, protected from light. Store at -20°C or below in a dry, cool place. This product is hygroscopic (moisture-sensitive). For long-term storage, keep desiccated. Allow the sealed vial to equilibrate to room temperature before opening to minimize moisture uptake.

Specification

Item	Specification
Appearance	Yellow to orange solid
Identification (HPLC)	Conforms
Identification (Mass Spectrometry)	Conforms
Assay (HPLC)	≥98.0%
Purity (HPLC, Area %)	≥95.0%
Water Content (KF)	≤5.0%
Residual Solvents (GC)	Meets ICH guidelines
Single Maximum Impurity (HPLC)	≤1.0%
Total Impurities (HPLC)	≤5.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.